Savient Pharmaceuticals, Inc.
Records under this name other than patents Savient Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Savient Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,148,123 | Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of Peg-Uricase Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,534,013 | Purification of Proteins With Cationic Surfactant Formerly held In force · High confidence | In force | High confidence | |
| US 9,377,454 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 10,139,399 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 10,823,727 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 11,598,767 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 11,639,927 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 11,982,670 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,188,927 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,811,800 | Variant Form of Urate Oxidase and Use Thereof Formerly held Term ended Term ended Apr 11, 2026 · High confidence | Term ended | Term ended Apr 11, 2026 | High confidence |